Zobrazeno 1 - 10
of 558
pro vyhledávání: '"Richard E Clark"'
Autor:
Alan K Burnett, Emma Das Gupta, Steve Knapper, Asim Khwaja, Marion Sweeney, Lars Kjeldsen, Timothy Hawkins, Sophie E Betteridge, Paul Cahalin, Richard E Clark, Robert K Hills, Nigel H Russell
Publikováno v:
Haematologica, Vol 103, Iss 10 (2018)
As part of the UK NCRI AML17 trial, adult patients with acute myeloid leukemia in remission could be randomized to receive the mammalian target of rapamycin inhibitor everolimus, sequentially with post-induction chemotherapy. Three hundred and thirty
Externí odkaz:
https://doaj.org/article/137ea70794c64954ac9332b82770f208
Autor:
Luke W Thomas, Connie Lam, Richard E Clark, Michael R H White, David G Spiller, Robert J Moots, Steven W Edwards
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e45088 (2012)
Mcl-1 is an anti-apoptotic member of the Bcl-2 family that plays a key role in normal development, but also in pathologies such as cancer. It has some unusual properties compared to other anti-apoptotic members of the Bcl-2 family, and its expression
Externí odkaz:
https://doaj.org/article/4a30f3e768d84efb811dd34fe11ce238
Autor:
Richard E. Clark
Richard Clark's observation that “…media are mere vehicles that deliver instruction but do not influence student achievement any more than the truck that delivers our groceries causes changes in our nutrition” is as misunderstood today as it wa
Autor:
Dragana Milojkovic, Alexander R. Lyon, Priyanka Mehta, Evangelia Dimitriadou, Satarupa Choudhuri, Charlotte Manisty, Nick Cheshire, Kirsty Crozier, Nanda Basker, Karim Amer, Simon Purcell, Susan Tan, Richard E. Clark
Publikováno v:
European Journal of Haematology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88cb9e08a95fea16a38c4ab9e66aa3a2
https://doi.org/10.1111/ejh.13983
https://doi.org/10.1111/ejh.13983
Autor:
Sonja Loges, Tessa L. Holyoake, G. Vignir Helgason, Carsten Bokemeyer, Klaus Pantel, Andreas Hochhaus, Peter Carmeliet, Tim H. Brümmendorf, Peter Vandenberghe, Subir Mitra, Alexander Schultze, Steffen Koschmieder, Richard E. Clark, Stephen Rankin, Janna L. Velthaus, Philippe Schafhausen, Gunhild von Amsberg, Thomas Ernst, Rebecca Mitchell, Heather Jørgensen, Robert Erdmann, Isabel Ben-Batalla
Purpose: BCR-ABL kinase inhibitors are employed successfully for chronic myeloid leukemia (CML) treatment. However, resistant disease and persistence of BCR-ABL1–independent leukemia stem and progenitor cells (LSPC) remain clinical challenges. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c4c9f65def4c57a65d58ae92abc93d8
https://doi.org/10.1158/1078-0432.c.6525134.v1
https://doi.org/10.1158/1078-0432.c.6525134.v1
Autor:
Jukka Westermarck, Maija Itälä-Remes, Claire M. Lucas, Venkata Kumari Bachanaboyina, Laura L. Elo, Richard E. Clark, Veli-Matti Kähäri, Tea Ammunét, Srikar G. Nagelli, Eliisa Löyttyniemi, Urpu Salmenniemi, Taru Varila, Karolina Pavic, Eleonora Mäkelä
Supplementary tables S1-S5 and supplementary figures S1-S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::719326290e46c0e1fbf0e57e719f057d
https://doi.org/10.1158/1078-0432.22479393.v1
https://doi.org/10.1158/1078-0432.22479393.v1
Autor:
Sonja Loges, Tessa L. Holyoake, G. Vignir Helgason, Carsten Bokemeyer, Klaus Pantel, Andreas Hochhaus, Peter Carmeliet, Tim H. Brümmendorf, Peter Vandenberghe, Subir Mitra, Alexander Schultze, Steffen Koschmieder, Richard E. Clark, Stephen Rankin, Janna L. Velthaus, Philippe Schafhausen, Gunhild von Amsberg, Thomas Ernst, Rebecca Mitchell, Heather Jørgensen, Robert Erdmann, Isabel Ben-Batalla
Figure S1. Inhibition of Axl by shRNA. Figure S2. Assessment of half maximal inhibitory concentration (IC50) for BGB324 in human CD34+ cells from healthy donors. Figure S3. Treatment with BGB324 increased apoptosis and decreased proliferation of CML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5afe9081732bbaa5bc72c766273976ad
https://doi.org/10.1158/1078-0432.22462538
https://doi.org/10.1158/1078-0432.22462538
Autor:
Jukka Westermarck, Maija Itälä-Remes, Claire M. Lucas, Venkata Kumari Bachanaboyina, Laura L. Elo, Richard E. Clark, Veli-Matti Kähäri, Tea Ammunét, Srikar G. Nagelli, Eliisa Löyttyniemi, Urpu Salmenniemi, Taru Varila, Karolina Pavic, Eleonora Mäkelä
Purpose:Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56α. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2A splicing variant, novel CIP2A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fafacee52720caa917ca11aea05890f
https://doi.org/10.1158/1078-0432.c.6530211
https://doi.org/10.1158/1078-0432.c.6530211
Autor:
Mhairi Copland, Daniel Slade, Graham McIlroy, Gillian Horne, Jenny L Byrne, Kate Rothwell, Kristian Brock, Hugues De Lavallade, Charles Craddock, Richard E Clark, Matthew L Smith, Rachel Fletcher, Rebecca Bishop, Dragana Milojkovic, Christina Yap
Publikováno v:
The Lancet Haematology. 9:e121-e132
Background: \ud Outcomes for patients with blast-phase chronic myeloid leukaemia are poor. Long-term survival depends on reaching a second chronic phase, followed by allogeneic haematopoietic stem-cell transplantation (HSCT). We investigated whether
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::682b9de44c3f06a8a96dd2efb0cda455
https://doi.org/10.1016/s2352-3026(21)00370-7
https://doi.org/10.1016/s2352-3026(21)00370-7
Autor:
Mhairi Copland, Ian Thomas, Nigel H. Russell, Richard E. Clark, Robert Kerrin Hills, Cono Ariti, Priyanka Mehta, Michael Dennis, Steven Knapper, Laura Upton, Rohini Radia, Amanda F. Gilkes, Claire Hemmaway, Alan K. Burnett
Publikováno v:
Blood Advances
Key Points First report of an FLT3-targeted therapy added to nonintensive chemotherapy that has improved survival in older FLT3-ITD patients with AML.Quizartinib is well tolerated, improves response and survival in older FLT3-ITD AML patients and mer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::947c8117ccc63e5664af5a159d9fb5a5
http://europepmc.org/articles/PMC8714727
http://europepmc.org/articles/PMC8714727